Condition: Lung Cancer (NSCLC) · Neoadjuvant Immunotherapy · Radiotherapy · Sponsor: Peking University Cancer Hospital & Institute
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.
This description comes directly from the study's public registry record.
Nan Wu, MD · 0086-10-88196569 · nanwu@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital & Institute | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Inner Mongolia Hospital of Peking University Cancer Hospital | Hohhot, Inner Mongolia, China | Recruiting |
| The Third Affliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06926179